Xbrane Biopharma releases interim report for January – September 2019

Xbrane secures financing for the Xplore study up until top-line data is received from all patients

Financial summary third quarter 2019

• Revenue amounted to SEK 0.0 M (2.4).
• Gross margin amounted to 0 percent (21).
• Other operating income amounted to SEK 1.4 M (84.0).
• EBITDA amounted to SEK -30.0 M (62.1).
• R&D expenses amounted to SEK -25.8 M (-12.0) representing 80 percent (54) of total operating expenses.
• Loss for the period amounted to SEK 32.4 M (60.1).
• Earnings per share amounted to SEK -2.24 (9.49).
• Cash and cash equivalents by the end of the period of SEK 162.2 M (64.3).

Financial summary first nine months 2019

• Revenue amounted to SEK 0.0 M (15.6).
• Gross margin amounted to 0 percent (21).
• Other operating income amounted to SEK 4.4 M (98.4).
• EBITDA amounted to SEK -103.4 M (24.3).
• R&D expenses amounted to SEK -90.1 M (-60.3) representing 84 percent (78) of total operating expenses.
• Loss for the period amounted to SEK 110.1 M (19.2).
• Earnings per share amounted to SEK-11.27 (3.11).

Significant events during the third quarter 2019

• A rights issue that began in the second quarter was completed and brought in SEK 91.1 M to the company before transaction costs.
• The company completed a change of trading site for its shares from the Nasdaq First North Growth Market to the Nasdaq Stockholm main list where the shares started trading on September 23, 2019.

Significant events after the third quarter 2019

• No significant events happened after the end of the quarter.